Core Insights - Kane Biotech Inc. has published an article on its revyve Antimicrobial wound gel in the International Wound Journal, highlighting the gel's wound healing properties and antimicrobial activity [1][2] Group 1: Publication and Validation - The article titled "Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity" is authored by Dr. Jeyachchandran Visvalingam and includes contributions from the University of Miami [1] - The publication in a peer-reviewed journal underscores the scientific rigor of revyve technology and provides independent validation of the gel's safety and clinical potential [3] Group 2: Product Efficacy and Features - The revyve Antimicrobial Wound Gel demonstrates efficacy against a range of wound-related pathogens, achieving a 99.99% to 99.9999% reduction in bacterial counts within 30 minutes [7] - The gel exhibits sustained in vitro activity for up to 7 days, potentially reducing the frequency of dressing changes [7] - It is designed as a thermo-reversible gel that transitions from a liquid to a gel at body temperature, allowing for easy removal [7] Group 3: Company Overview - Kane Biotech is focused on developing novel wound care treatments that target biofilms, which contribute to antibiotic resistance and adverse clinical outcomes [4] - The revyve product line, including the Antimicrobial Wound Gel and Spray, has received U.S. FDA 510(k) clearance and Health Canada approval [4]

Core Insights - Kane Biotech Inc. has signed non-exclusive distribution and sales agreements for its revyve Antimicrobial Wound Gel product line with Patient Care Medical and Life Biologics, enhancing its market presence in the U.S. [1][2] Group 1: Distribution Agreements - The agreements with Patient Care Medical and Life Biologics will expand Kane Biotech's presence in targeted sales channels and geographic markets, with Life Biologics distributing nationally and Patient Care Medical focusing on Louisiana, Mississippi, and the Gulf Coast [2][3] - Initial shipments of the revyve product line are being prepared for the near term [2] Group 2: Company Strategy and Product Information - Expanding the U.S. distribution network is a key priority for Kane Biotech, supporting its near-term commercialization objectives [3] - Kane Biotech is focused on developing novel wound care treatments that disrupt biofilms, which contribute to antibiotic resistance in wounds, with its revyve product line addressing both biofilms and wound bacteria [3] - The revyve Antimicrobial Wound Gel and its variants are U.S. FDA 510(k) cleared and Health Canada approved, indicating regulatory compliance and market readiness [3]

Core Insights - Kane Biotech Inc. has achieved significant regulatory milestones that enhance its wound care platform and commitment to high-quality medical device development [1] Regulatory Approvals - The company has received FDA 510(k) clearance for its revyve Antimicrobial Skin and Wound Cleanser, which is designed for the cleansing and moistening of various acute and chronic dermal lesions, including pressure ulcers and diabetic foot ulcers [2] - This clearance validates Kane's expanded revyve product line, which targets wound bacteria and biofilms, key factors in delayed healing and antibiotic resistance [2] Certification Expansion - Kane has expanded its ISO 13485:2016 certification under the Medical Device Single Audit Program (MDSAP) to include distribution and wound cleansers, building on existing certifications for nonsterile antimicrobial wound dressings [3] - This expansion aligns with the FDA's new Quality Management System Regulation (QMSR) effective February 2026, harmonizing U.S. requirements with ISO 13485 [3] Commitment to Quality - The expanded certification supports Kane's ability to pursue regulatory approvals across multiple jurisdictions and demonstrates its investment in quality systems and operational readiness [4] - The Chief Quality Officer emphasized that compliance with ISO 13485 and MDSAP enhances trust among healthcare providers and patients, ensuring alignment with evolving regulatory expectations [5]

Company enters 2026 with renewed business momentum and key commercial appointments in the U.S. and CanadaWINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces the resumption of commercial activities in both the United States and Canada for its revyve® Antimicrobial Wound Gel product line, alongside the appointment of two seasoned industry leaders to drive business development across North America. US FDA 510(k) cleared ...

Core Insights - Kane Biotech presented new clinical and scientific data at the Innovations in Wound Healing Annual Meeting, emphasizing its commitment to addressing complex health conditions [1][2] - The company showcased its FDA cleared and Health Canada approved revyve Antimicrobial Wound Gel and Spray, highlighting their role in improving patient outcomes [4][5] Company Developments - Kane Biotech shared case study data demonstrating improved healing trajectories in chronic wounds using its advanced wound gel platform [5] - New findings were presented regarding the effectiveness of Kane's wound gel technology in treating Chronic Radiation-Induced Achilles Ulcer, where conventional therapies often fail [5] - Data on Hidradenitis Suppurativa (HS) illustrated the potential of revyve to reduce infection burden and improve outcomes in this condition [5] Market Insights - The presentations reflected how Kane's innovations are being integrated into care pathways, delivering measurable value to health systems [5] - The company is focused on developing novel wound care treatments that disrupt biofilms, which contribute to antibiotic resistance and serious clinical outcomes [6]

Core Insights - Kane Biotech Inc. has received Health Canada approval for its revyve Antimicrobial Wound Gel Spray, marking a significant regulatory achievement for the company in the Canadian market [1][2][4] Product Overview - The revyve Antimicrobial Wound Gel Spray is designed to assist clinicians in managing complex wounds by reducing microbial burden and promoting a healthier wound environment [2][3] - This product is part of Kane Biotech's revyve wound care portfolio, which has been evaluated in various clinical settings in the United States [3] Market Impact - The approval provides Canadian clinicians and patients with a new option for managing burns, large surface area wounds, and ulcers, enhancing the available wound care solutions [3][4] - The company aims to collaborate with healthcare partners and distributors to ensure proper access and education regarding the use of the revyve Antimicrobial Wound Gel Spray [4] Company Strategy - Kane Biotech is committed to advancing its wound care portfolio, including the recent FDA submission of the revyve Antimicrobial Wound and Skin Cleanser, which will be the third product in its revyve line [4][6] - The company focuses on developing novel wound care treatments that disrupt biofilms, which are significant contributors to antibiotic resistance in wounds [6]

Core Insights - Kane Biotech Inc. reported its third quarter 2025 financial results, highlighting a significant decline in revenue compared to the same period in 2024, primarily due to the termination of an animal health manufacturing agreement and a US distribution agreement for its revyve product [7] Financial Performance - Total revenue for Q3 2025 was $8,499, a decrease from $1,282,698 in Q3 2024 [7] - Gross profit (loss) for Q3 2025 was $(5,128), compared to a gross profit of $558,754 in Q3 2024 [7] - Total operating expenses for Q3 2025 were $538,306, down from $1,170,064 in Q3 2024, attributed to staff reductions and lower compensation and business development costs [7] - Net loss for Q3 2025 was $(607,345), an improvement from a net loss of $(678,636) in Q3 2024 [7] - Cash as of September 30, 2025, was $939,062 [7] Clinical Developments - Kane Biotech is advancing its three-pillar strategy in wound care, with successful enrollment of 28 participants in its revyve Antimicrobial Wound Gel and Spray U.S. Case Series Studies, surpassing the target of 25 participants [2] - Clinical data presented at the Symposium on Advanced Wound Care (SAWC) Fall conference indicated promising results for revyve, with significant engagement from potential U.S. distributors [3] - New clinical data from The Diabetic Foot Conference (DFCon 2025) showed an average 97% area wound reduction in diabetic foot ulcers within four weeks and 100% wound closure in less than 12 weeks [4] - Pre-clinical data presented at the Southern Region Burn Conference demonstrated a six-log reduction in microbial load within 30 minutes using revyve, with sustained antibiofilm activity for at least seven days [5] Strategic Initiatives - The company plans to conduct further U.S.-based case series studies and report data at leading wound and burn care meetings [8] - Kane Biotech has submitted a 510(k) clearance application to the U.S. FDA for its revyve Antimicrobial Wound Cleanser and is working to establish a network of non-exclusive distributors and sales agents in the U.S. [9] - The Interim CEO emphasized the importance of the clinical data and distributor network in launching revyve in Canada and improving patient outcomes [10]

Core Viewpoint - Kane Biotech Inc. is planning a non-brokered private placement offering of up to 16 million common shares at a price of $0.05 per share, aiming for gross proceeds of up to $800,000 [1][2]. Group 1: Offering Details - The net proceeds from the offering will be allocated for working capital and general corporate purposes [2]. - The closing of the offering is anticipated to occur around December 17, 2025 [2]. - All shares issued will be subject to a hold period of four months and one day from the issuance date [2]. Group 2: Company Overview - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which contribute to antibiotic resistance in wounds [4]. - The company's products, including revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray, have received US FDA 510(k) clearance and Health Canada approval [4].

Core Insights - Kane Biotech Inc. announced new clinical and pre-clinical data showcasing the effectiveness of its FDA-cleared revyve Antimicrobial Wound Gel and revyve Wound Gel Spray in diabetic foot ulcer healing and burn wound infection control [1] Clinical Data: Outperforming the Standard of Care - At the Diabetic Foot Conference 2025, data presented indicated that revyve achieved healing outcomes surpassing the current standard of care for diabetic foot ulcers, with an average percent area reduction (PAR) of 97% in 4 weeks compared to the 40-50% benchmark [2][7] - Complete wound closure was achieved in all cases within 8-12 weeks across a multi-center series [7] - The gel effectively managed bacterial loads, aiding patients with conditions such as Peripheral Arterial Disease and elevated A1c levels [3] Rapid Antimicrobial Efficacy in Burn Care - At the Southern Region Burn Conference, pre-clinical data showed a 99.99% to 99.9999% reduction in burn-associated pathogens within 30 minutes of application, with sustained antibiofilm activity for a minimum of 7 days [4][8] - The product's ability to achieve up to a six-log reduction in microbial load within minutes represents a significant advancement in burn wound management [8] Company Strategy and Future Outlook - These findings are part of Kane's three-pillar strategy aimed at significantly impacting wound care in the United States, emphasizing the potential of revyve's antibiofilm and antimicrobial technology to transform wound healing outcomes [8] - Kane Biotech is focused on developing novel wound care treatments that disrupt biofilms, which are major contributors to antibiotic resistance in wounds [11]

Core Insights - Kane Biotech Inc. has completed a U.S. FDA 510(k) clearance submission for its revyve Antimicrobial Wound Cleanser, marking a significant step in its product development [1][2] Product Development - The revyve Antimicrobial Wound Cleanser is the third product in the revyve line, complementing the existing revyve Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray [2] - This new product aims to enhance routine wound management by providing irrigation to cleanse both acute and chronic wounds, thereby reducing bacterial load and removing debris [2] Market Opportunity - The annual U.S. market size for wound cleansers surpassed $200 million USD in 2024, indicating a substantial market opportunity for Kane Biotech's new product [3]